CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Eli Lilly and Company
Summary
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Eligibility
- Age range
- 1–39 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Participants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll. * Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). * The participant has a Lansky (\<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50. * Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 da…
Interventions
- DrugRamucirumab
Administered IV
- DrugCyclophosphamide
Administered orally
- DrugVinorelbine
Administered IV
- DrugGemcitabine
Administered IV
- DrugDocetaxel
Administered IV
- DrugAbemaciclib
Administered orally
- DrugIrinotecan
Administered IV
Locations (73)
- Childrens Hospital of AlabamaBirmingham, Alabama
- Phoenix Children's HospitalPhoenix, Arizona
- Phoenix Children's HospitalPhoenix, Arizona
- Childrens Hospital of Los AngelesLos Angeles, California
- UCLA Medical CenterLos Angeles, California
- Children's Hospital of Orange CountyOrange, California